Shattuck Labs share price more than doubled Wednesday premarket after the company said its blood cancer therapy achieved a 79% objective response rate in a phase 1a/b trial.
ImmunoPrecise.
Shattuck Labs shares soared nearly 101% in recent Wednesday trading, extending earlier gains after the company said its blood cancer therapy achieved a 79% objective response rate in a phase 1a/b.
- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose. | May 25, 2023
— Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer to be presented at the 2023 American Society of Clinical Oncology annual meeting. | May 9, 2023